公开(公告)号：US12214006B2

公开(公告)日：2025-02-04

申请号：US18467250

申请日：2023-09-14

Applicant: Hunan University of Science and Engineering

Inventor： Zongcheng Wang ,  Yuanfei Xu ,  Zuodong Qin ,  Zhenmin Cao ,  Xiaofang Luo ,  Chen Gui ,  Shuwen Wang ,  Asad Nawaz ,  Manting Li

IPC: A61K36/288 ,  A61K9/06 ,  A61K31/045 ,  A61K36/35 ,  A61K36/355 ,  A61K38/10 ,  A61K47/14 ,  A61K47/44 ,  A61P31/04

Abstract: Provided are a traditional Chinese medicine ointment for preventing and treating mastitis in dairy cows and a preparation method thereof, belonging to the technical field of veterinary traditional Chinese medicines. The traditional Chinese medicine ointment includes raw materials in parts by mass: 20-30 parts of dandelion, 20-30 parts of herba patriniae, 10-16 parts of Caulis Lonicerae Japonicae, 0.5-1 part of borneol, 0.03-0.05 part of polypeptide, 40-50 parts of auxiliary emulsifier, 40-50 parts of liquid paraffin and 100-130 parts of white vaseline. An amino acid sequence of the polypeptide is: Phe Phe Arg Lys Val Leu Lys Leu Ile Arg Lys Ile Trp Arg (SEQ ID NO. 1). In the application, dandelion, herba patriniae, Caulis Lonicerae Japonicae and borneol 1 are mixed, and polypeptide is added at the same time to prepare ointment.

公开(公告)号：US20250018042A1

公开(公告)日：2025-01-16

申请号：US18444413

申请日：2024-02-16

Applicant: The General Hospital Corporation

Inventor： Lilit Garibyan ,  Richard Rox Anderson ,  William A. Farinelli ,  Emilia Javorsky

IPC: A61K45/06 ,  A61K9/00 ,  A61K31/045 ,  A61K31/047 ,  A61K31/137 ,  A61K31/167 ,  A61K31/245 ,  A61K31/445 ,  A61K31/7004 ,  A61K31/718 ,  A61K31/765 ,  A61K33/00 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/28

Abstract: One aspect of the invention provides a slurry comprising: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible surfactant. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; a biocompatible surfactant; and a foam comprising a plurality of gas bubbles. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible excipient. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a lipolytic agent.

公开(公告)号：US20240390396A1

公开(公告)日：2024-11-28

申请号：US18687448

申请日：2022-08-29

Applicant: ARIEL SCIENTIFIC INNOVATIONS LTD.

Inventor： Noa DAVIS ,  Igor KOMAN ,  Natalya M. KOGAN

IPC: A61K31/00 ,  A61K31/045 ,  A61K31/05 ,  A61K31/125 ,  A61K31/165 ,  A61K31/365 ,  A61K31/55 ,  A61P35/00

Abstract: The present invention discloses a pharmaceutical composition including a cannabinoid and a transient receptor potential cation channel (TRP) ligand, and methods of using same, such as for treating a subject afflicted with a cell proliferation related disease, or alleviating a symptom associated therewith.

公开(公告)号：US20240350519A1

公开(公告)日：2024-10-24

申请号：US18615236

申请日：2024-03-25

Applicant: Quicksilver Scientific, Inc.

Inventor： Christopher W. Shade ,  Steven Tieu ,  James R Huey ,  David Durkee ,  Michelle Schwenk

IPC: A61K31/00 ,  A23G3/34 ,  A23G3/36 ,  A23G3/40 ,  A23G3/42 ,  A23G3/44 ,  A23G3/48 ,  A61K9/00 ,  A61K9/107 ,  A61K31/01 ,  A61K31/015 ,  A61K31/045 ,  A61K31/07 ,  A61K31/122 ,  A61K31/197 ,  A61K31/198 ,  A61K31/205 ,  A61K31/355 ,  A61K31/375 ,  A61K31/593 ,  A61K33/30 ,  A61K36/185 ,  A61K36/539 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/24 ,  A61K47/26 ,  A61K47/42 ,  A61K47/44

CPC classification number: A61K31/658 ,  A23G3/0019 ,  A23G3/368 ,  A23G3/40 ,  A23G3/42 ,  A23G3/44 ,  A23G3/48 ,  A61K9/0056 ,  A61K9/1075 ,  A61K31/01 ,  A61K31/015 ,  A61K31/045 ,  A61K31/07 ,  A61K31/122 ,  A61K31/197 ,  A61K31/198 ,  A61K31/205 ,  A61K31/355 ,  A61K31/375 ,  A61K31/593 ,  A61K33/30 ,  A61K36/185 ,  A61K36/539 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/24 ,  A61K47/26 ,  A61K47/42 ,  A61K47/44

Abstract: Microemulsions incorporated into gummy confections are described where hydrophobic liquid droplets are distributed in a continuous hydrophilic liquid phase. In relation to conventional oil-in-water (OIW) microemulsions, prior to incorporation into the gummy confections the described microemulsions may be thought of as modified oil-in-water (MOIW) microemulsions, where both the “oil” and “water” phases of the microemulsion are modified. The oil phase droplets of the MOIW microemulsion are modified with alcohol and can better deliver oil-soluble species to the bloodstream than can oil blends or the oil phases of conventional oil-in-water (OIW) microemulsions. The polar continuous “water” phase of the MOIW microemulsion is modified with a sugar or sugar alcohol. The modified oil phase droplets disperse into the modified polar continuous phase of the MOIW microemulsion prior to incorporation into the gummy confection.

公开(公告)号：US20240350407A1

公开(公告)日：2024-10-24

申请号：US18762026

申请日：2024-07-02

Applicant: SENSORY CLOUD, LLC

Inventor： David A. Edwards ,  Tom Devlin

IPC: A61K9/00 ,  A23L33/105 ,  A61K31/045 ,  A61K31/202 ,  A61K31/465 ,  A61K35/00 ,  A61K36/185 ,  A61K36/22 ,  A61K36/42 ,  A61K36/54 ,  A61K36/73 ,  A61K36/752 ,  A61K36/81 ,  A61K36/8962 ,  A61K36/899 ,  A61K36/9068 ,  A61K45/06 ,  A61M11/00 ,  A61M15/00 ,  A61M15/08

CPC classification number: A61K9/0078 ,  A23L33/105 ,  A61K31/045 ,  A61K31/202 ,  A61K31/465 ,  A61K35/00 ,  A61K36/185 ,  A61K36/22 ,  A61K36/42 ,  A61K36/54 ,  A61K36/73 ,  A61K36/752 ,  A61K36/81 ,  A61K36/8962 ,  A61K36/899 ,  A61K36/9068 ,  A61K45/06 ,  A61M11/003 ,  A61M15/0003 ,  A61M15/009 ,  A61M15/08 ,  A23V2002/00 ,  A61M2205/0294 ,  A61M2205/50

Abstract: A composition of food or therapeutic and other substances for administration as a cloud of droplets, the cloud comprising readily-soluble droplets having a median size range of approximately 3 microns to approximately 20 microns, or 5 microns to 10 microns, or 6 microns to 10 microns, for introduction to an animal via an ortho-nasal or retro-nasal route. Agonists or antagonists may include one or more of the following: sodium iodide, sodium chloride, magnesium chloride, capsaicin, piperine, linalool, ground cinnamon, a cannabinoid, pimento, onion, clove, thyme, ginger, menthol, or TRPV antagonists, and chocolate, Irish cream, caramel, lemon, lime, mango, raspberry, watermelon, blueberry, strawberry, mint, popcorn, meat, Resolvin D2 or nicotine. Devices for delivering compositions as an aerosol are described.

公开(公告)号：US12121499B2

公开(公告)日：2024-10-22

申请号：US17576868

申请日：2022-01-14

Applicant: GW Pharma Limited

Inventor： Benjamin Whalley ,  Claire Williams ,  Gary Stephens ,  Thomas Hill

IPC: A61K31/05 ,  A61K31/045 ,  A61K31/352 ,  A61K31/353 ,  A61K36/185 ,  A61K45/06

CPC classification number: A61K31/05 ,  A61K31/045 ,  A61K31/352 ,  A61K31/353 ,  A61K36/185 ,  A61K45/06 ,  A61K31/05 ,  A61K2300/00 ,  A61K31/045 ,  A61K2300/00 ,  A61K31/352 ,  A61K2300/00

Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and/or CBD.

公开(公告)号：US12115220B2

公开(公告)日：2024-10-15

申请号：US17309186

申请日：2019-11-05

Applicant: Inspired Material Solutions, LLC

Inventor： Mark A. Latta

IPC: A61K36/00 ,  A61K9/00 ,  A61K31/02 ,  A61K31/045 ,  A61K31/047 ,  A61K31/085 ,  A61K31/14 ,  A61K31/155 ,  A61K31/167 ,  A61K31/221 ,  A61K31/245 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/4425 ,  A61K31/7036 ,  A61K31/714 ,  A61K31/717 ,  A61K33/00 ,  A61K33/06 ,  A61K33/16 ,  A61K33/30 ,  A61K33/40 ,  A61K33/42 ,  A61K35/644 ,  A61K36/185 ,  A61K36/28 ,  A61K36/484 ,  A61K36/537 ,  A61K36/889 ,  A61K38/12 ,  A61K47/34

CPC classification number: A61K47/34 ,  A61K9/006 ,  A61K31/02 ,  A61K31/045 ,  A61K31/047 ,  A61K31/085 ,  A61K31/14 ,  A61K31/155 ,  A61K31/167 ,  A61K31/221 ,  A61K31/245 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/4425 ,  A61K31/7036 ,  A61K31/714 ,  A61K31/717 ,  A61K33/00 ,  A61K33/06 ,  A61K33/16 ,  A61K33/30 ,  A61K33/40 ,  A61K33/42 ,  A61K35/644 ,  A61K36/185 ,  A61K36/28 ,  A61K36/484 ,  A61K36/537 ,  A61K36/889 ,  A61K38/12

Abstract: An oral mucosal carrier comprising a combination of two different viscosity dimethicone components, wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater; and comprising at least one active agent.

公开(公告)号：US12090178B2

公开(公告)日：2024-09-17

申请号：US17831930

申请日：2022-06-03

Applicant: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.

Inventor： Ashley Dombkowski ,  Christopher Cornyn ,  Albert E. Rosevear ,  Olivia M. Weihe ,  Cosmin M. Beliciu ,  Alexandra F. Russell ,  Antoinette de Senna

IPC: A61K36/00 ,  A23L5/30 ,  A23L29/30 ,  A23L33/00 ,  A23L33/105 ,  A23L33/155 ,  A23L33/185 ,  A23L33/19 ,  A61K9/00 ,  A61K31/045 ,  A61K35/57 ,  A61K35/60 ,  A61K35/63 ,  A61K36/185 ,  A61K36/22 ,  A61K36/48 ,  A61K36/52 ,  A61K36/736 ,  A61K36/899

CPC classification number: A61K35/63 ,  A23L5/34 ,  A23L29/35 ,  A23L33/105 ,  A23L33/155 ,  A23L33/185 ,  A23L33/19 ,  A23L33/40 ,  A61K9/0056 ,  A61K31/045 ,  A61K35/57 ,  A61K35/60 ,  A61K36/185 ,  A61K36/22 ,  A61K36/48 ,  A61K36/52 ,  A61K36/736 ,  A61K36/899 ,  A23V2002/00

Abstract: Methods of making mixed allergen compositions, e.g., substantially aerobic organism free mixed allergen compositions, and the resulting allergen composition, are provided.

公开(公告)号：US20240277976A1

公开(公告)日：2024-08-22

申请号：US18644498

申请日：2024-04-24

Applicant: Lixiao Wang ,  Neurotronic, Inc.

Inventor： Lixiao Wang ,  John J. Chen ,  Yongxing Zhang

IPC: A61M25/10 ,  A61B18/00 ,  A61B18/06 ,  A61K31/045 ,  A61M5/00 ,  A61M5/142 ,  A61M5/172 ,  A61M29/02

CPC classification number: A61M25/1002 ,  A61B18/06 ,  A61K31/045 ,  A61M5/007 ,  A61M5/142 ,  A61M5/172 ,  A61M25/1011 ,  A61M29/02 ,  A61B2018/00577 ,  A61M2025/105 ,  A61M2025/1052 ,  A61M2202/02

Abstract: Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

公开(公告)号：US20240269089A1

公开(公告)日：2024-08-15

申请号：US18624108

申请日：2024-04-01

Applicant: Andrea Small-Howard ,  Helen Turner

Inventor： Andrea Small-Howard ,  Helen Turner

IPC: A61K31/01 ,  A61K9/00 ,  A61K31/015 ,  A61K31/045 ,  A61K31/05 ,  A61K31/192 ,  A61K31/352 ,  A61K36/185 ,  A61K45/06 ,  A61P29/02

CPC classification number: A61K31/01 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/006 ,  A61K9/0073 ,  A61K31/015 ,  A61K31/045 ,  A61K31/05 ,  A61K31/192 ,  A61K31/352 ,  A61K36/185 ,  A61K45/06 ,  A61P29/02 ,  A61K2236/51

Abstract: Provided herein are pharmaceutical compositions that comprise myrcene, optionally in admixture with cannabinoids and other terpenes, typically substantially free of THC and THCA, for targeting TRPV1 receptors. Also provided are methods of using the pharmaceutical compositions to desensitize TRPV1 receptors in order to treat pain, cardiovascular diseases such as cardiac hypertrophy, overactive bladder, and chronic cough.